Unicycive Announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets
Unicycive Therapeutics, Inc. Expands and accelerates Renazorb opportunity in important markets for patients with hyperphosphatemia through local partner with deep domain expertise Agreement includes upfront payment, royalties and milestone payments LOS ALTOS, Calif., July 18, 2022 (GLOBE NEWSWIRE...